红细胞趋化因子受体在抗肿瘤免疫反应中的作用  

The Role of Erythrocyte Chemokine Receptors in The Neoplasm Immunity

作　　者：查占山[1] 钱宝华[1] 郭峰[1] 

机构地区：[1]第二军医大学附属长海医院,上海200433

出　　处：《肿瘤学杂志》2005年第3期228-230,共3页Journal of Chinese Oncology

摘　　要：红细胞趋化因子受体是一个G蛋白非偶联的杂性趋化因子受体,可作为趋化因子“清除槽”或诱骗受体,吸附肿瘤局部过多的血管生成性趋化因子,使肿瘤血管生成减少,阻止肿瘤生长和转移。肿瘤患者红细胞趋化因子受体活性有明显下降,使肿瘤局部免疫状态低下,利于肿瘤细胞生长和转移。Erythrocyte chemokine receptor is a promiscuous chemokine receptor which is not coupled by G-protein. It can sequester angiogenic chemokines from the neoplasm loci by acting as a 'chemokine sink' or 'decoy receptor'. It can inhibit neovascularization growth and metastasis of the neoplasms. Activity of the erythrocyte chemokine receptors in the cancer patients decreased significantly, resulting in the patients' immunity decrease, which is predisposing to cancer growth and metastasis.

关 键 词：红细胞 受体 趋化凶子 肿瘤 免疫 

分 类 号：R73-362[医药卫生—肿瘤]